Navigation Links
Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia
Date:12/10/2008

AEs among the reported psychiatric disorders were insomnia (both groups 15%), psychotic disorder (PP+Pbo 14%; RIS+RIS 12%) schizophrenia (PP+Pbo 12%; RIS+RIS 9%) and anxiety (PP+Pbo 10%; RIS+RIS 15%). Adverse events leading to discontinuation occurred in 7% of PP+Pbo patients and 6% of LAT RIS+RIS patients. Based on these results, an additional phase III study is being conducted to further assess the dosing regimen of paliperidone palmitate 150 mg eq. followed by a second injection of 100 mg eq. with subsequent injections every four weeks, compared with risperidone LAT.

"These findings will help us determine the best dosing strategy for paliperidone palmitate in the treatment of schizophrenia," said lead author, Professor Wolfgang Fleischhacker, Dept of Psychiatry and Psychotherapy, Medical University Innsbruck*. "This could provide a valuable option for healthcare professionals to help people who are struggling with this illness."

INVEGA(R) (paliperidone) Extended-Release Tablets, the oral formulation of paliperidone, was first approved in 2006 in the U.S. for the acute treatment of schizophrenia. In March 2007, INVEGA was approved for the maintenance treatment of schizophrenia in the U.S. It was also approved for the treatment of schizophrenia in the European Union in June 2007.

Worldwide, it is estimated that one person in every 100 develops schizophrenia, one of the most serious types of mental illness(4). An estimated 2.4 million Americans have schizophrenia, with men and women affected equally(5). The disease is marked by positive symptoms (hallucinations and delusions) and negative symptoms (depression, blunted emotions, and social withdrawal), as well by disorganized thinking, speech and behavior.

The study was sponsored by Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD). Once approved, Janssen, Division of Ortho-McNeil-Janssen Pharmace
'/>"/>

SOURCE Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers
2. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
3. Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
4. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
5. AcelRx Pharmaceuticals Reports Positive Results From a Phase 2 Clinical Trial of Sublingual Sufentanil NanoTabs(TM) in Treating Post-Operative Pain
6. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
7. MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor
8. Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411
9. SemBioSys begins phase I/II trial of insulin produced in plant seeds
10. Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH
11. OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... BioClinica®, Inc., a leading provider of outsourced ... of its experts are speaking at the 20th ... be held September 28 to October 1 in ... announced the innovative Compass technology, a risk-based ... acquired earlier this year, is up for the ...
(Date:9/17/2014)... Intarcia Therapeutics, Inc. today announced ... of the cost and predictability of non-adherence in type ... Meeting of the European Association for the Study of ... Frois , Ph.D., of Analysis Group, Inc. presented data ... retrospective studies to characterize the prevalence of non-adherence and ...
(Date:9/17/2014)... - SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: SQIDF), a ... and products for advanced microarray diagnostics, today announced that ... the United States on the ... September 17, 2014 on the OTCQX under the symbol ... TSX Venture Exchange under its existing symbol SQD. ...
(Date:9/17/2014)... FOREST, California , 17 de septiembre ... CYRX) ("la compañía"), principal proveedor mundial de ... de las ciencias de la vida, anunció ... compañía de logística global con sede en ... su base de clientes Europa en rápido ...
Breaking Biology Technology:BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5
... Tiny chemical particles emitted by diesel exhaust fumes could raise ... have found that ultrafine particles produced when diesel burns are ... blood clots forming in arteries, leading to a heart attack ... measured the impact of diesel exhaust fumes on healthy volunteers ...
... interview with a researcher, please contact the Communications and External ... For more information on ORNL and its research and development ... you have a general media-related question or comment, you can ... Moving toward nanorobots . . . Nanoscale robots ...
... FALLS, Idaho,  July 13, 2011 International Isotopes ... nuclear medicine products, is pleased to announce it ... construction, technical, and management services firm, as the ... depleted uranium de-conversion facility in Lea County, New ...
Cached Biology Technology:Diesel fumes pose risk to heart as well as lungs, study shows 2Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2011 2Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2011 3Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2011 4International Isotopes Inc. Announces the Selection of Parsons as the Lead Design-Build Contractor for the Proposed Depleted Uranium De-Conversion Facility 2International Isotopes Inc. Announces the Selection of Parsons as the Lead Design-Build Contractor for the Proposed Depleted Uranium De-Conversion Facility 3International Isotopes Inc. Announces the Selection of Parsons as the Lead Design-Build Contractor for the Proposed Depleted Uranium De-Conversion Facility 4
(Date:9/17/2014)... Spanish researchers have obtained the first partial genome sequence ... pig found at the site of the Montsoriu Castle ... pig is closely related to today,s Iberian pig. Researchers ... with modern Iberian pigs. , The study, published in ... of pig species, and particularly on that of the ...
(Date:9/17/2014)... 2014 Researchers at UTSouthwestern Medical Center have found ... apolipoprotein E, called apoE3, helps repair the lining of ... not get the benefit of this repair, putting them ... that we have identified one mechanism by which apoE3 ... variant, apoE4, is detrimental," said Dr. Philip Shaul ...
(Date:9/17/2014)... been growing significantly faster since the 1960s. The typical ... but they have accelerated -- by as much as ... carried out by scientists from Technische Universitt Mnchen based ... been continuously observed since 1870. Their findings were published ... ago, "forest dieback" was a hot topic, with the ...
Breaking Biology News(10 mins):Iberian pig genome remains unchanged after 5 centuries 2Protein variant may boost cardiovascular risk by hindering blood vessel repair 2Global change: Trees continue to grow at a faster rate 2Global change: Trees continue to grow at a faster rate 3
... the results of the Oats at 10 Years study, marking ... claim that oats, as part of an overall heart healthy ... written by Mark B. Andon, PhD, and James W. Anderson, ... claim, theorizing that foods containing whole-oat sources of soluble fiber ...
... University bioengineer Jennifer West is being recognized today with ... the O,Donnell Award from The Academy of Medicine, Engineering ... given for excellence in medical, scientific and engineering research, ... statue. West, a pioneer in the field of biomaterials ...
... of Alberta for those who may have overindulged during the recent ... a way to reduce the amount of bad cholesterol and fatty ... metabolizes, a key discovery that could lead to new drugs to ... disease related to obesity. In a series of recently ...
Cached Biology News:Rice's West honored as one of Texas' best researchers 2Rice's West honored as one of Texas' best researchers 3University of Alberta researchers report breakthrough in lowering bad cholesterol, fatty acid levels 2